Develops neurology therapies, focusing on treatments for neurodegenerative diseases using gene therapy approaches.
Quince Therapeutics, Inc. is a pioneering biopharmaceutical firm dedicated to advancing precision therapies for rare and debilitating diseases. Established in 2012 and based in South San Francisco, California, Quince Therapeutics specializes in developing innovative treatments that target specific medical needs with a focus on bone health and fracture repair.
At the forefront of its research efforts is a groundbreaking bone-targeting drug platform designed to deliver small molecules, peptides, and large molecules precisely to sites of bone fracture and disease. Central to its pipeline is NOV004, a leading anabolic peptide meticulously engineered to concentrate and effectively address bone fractures. This innovative approach underscores Quince Therapeutics' commitment to revolutionizing treatment options for patients suffering from bone-related conditions.
Formerly known as Cortexyme, Inc., the company rebranded to Quince Therapeutics, Inc. in August 2022, reflecting its strategic evolution and expanded focus on advancing novel therapies in the biopharmaceutical landscape. With a steadfast dedication to scientific innovation and patient-centric solutions, Quince Therapeutics continues to pave the way in developing transformative treatments that offer hope and improved outcomes for individuals affected by rare and challenging diseases.